Tempus AI (TEM) and Blood Cancer United announced a strategic collaboration to develop a real-world registry for pediatric acute myeloid leukemia, a rare and aggressive blood cancer.
Meet Samuel – Your Personal Investing Prophet
High conviction TEM bulls now have this Tradr ETFPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Cathie Wood Invests Over $10M in CRISPR and PAYP Stocks, Trims Stakes in TER and IONS
- Tempus AI: Underappreciated Oncology Platform and Data Business Poised for Reimbursement Upside and AI-Driven Growth
- Tempus AI Earnings Call Highlights Strong Growth Path
- Tempus AI price target raised to $95 from $89 at H.C. Wainwright
- Tempus AI management to meet with Needham